HRT Financial’s ADMA Biologics ADMA Stock Holding History

HRT Financial’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.8M	Buy	+1,195,051	New	+$18.9M	0.03%	595
2025 Q4	–	Sell	-36,764	Closed	-$538K	–	3106
2025 Q3	$538K	Buy	+36,764	New	+$630K	﹤0.01%	1852
2025 Q2	–	Sell	-75,785	Closed	-$1.5M	–	2513
2025 Q1	$1.5M	Buy	+75,785	New	+$1.31M	0.01%	937
2024 Q2	–	Sell	-98,656	Closed	-$651K	–	2138
2024 Q1	$651K	Sell	98,656 -133,355	-57%	-$729K	﹤0.01%	1113
2023 Q4	$1.05M	Sell	232,011 -17,495	-7%	-$64.7K	0.01%	961
2023 Q3	$893K	Buy	249,506 +50,872	+26%	+$196K	0.01%	1049
2023 Q2	$732K	Buy	+198,634	New	+$736K	0.01%	1141
2023 Q1	–	Sell	-621,348	Closed	-$2.41M	–	2421
2022 Q4	$2.41M	Buy	+621,348	New	+$1.92M	0.03%	506
2021 Q4	–	Sell	-118,099	Closed	-$133K	–	3093
2021 Q3	$133K	Buy	118,099 +40,158	+52%	+$56.3K	﹤0.01%	2820
2021 Q2	$124K	Buy	77,941 +12,177	+19%	+$21.4K	﹤0.01%	2538
2021 Q1	$115K	Buy	+65,764	New	+$151K	﹤0.01%	2439
2020 Q3	–	Sell	-11,478	Closed	-$33K	–	1840
2020 Q2	$33K	Buy	+11,478	New	+$33K	﹤0.01%	1351

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

HRT Financial's ADMA Position: Q1 2026 in Review

HRT Financial opened a new position in ADMA Biologics (ADMA) in Q1 2026: 1,195,051 shares worth $10.8M. The stake represents 0.03% of the portfolio and ranks #595 among its holdings. This is a return to the name: HRT Financial previously reported a position in ADMA as recently as Q3 2025.

HRT Financial first reported a position in ADMA in Q2 2020 and has held it in 12 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

HRT Financial held 1,195,051 shares of ADMA Biologics worth $10.8M as of Q1 2026.
ADMA Biologics was a new HRT Financial position in Q1 2026.
ADMA Biologics made up 0.03% of HRT Financial's portfolio in Q1 2026, its #595 holding.
HRT Financial first reported a position in ADMA Biologics in Q2 2020 and has held it in 12 quarters since.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.